Here's What You May Have Missed About Grifols (GRFS)

By Emilio Sanchez • Thursday, January 12 12:02 • Permanent Link

Grifols marked a 2.9% change today, compared to 0.2% for the S&P 500. Is it a good value at today's price of $9.31? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.
Grifols belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07
The company's P/B ratio is 2.0
Grifols has a trailing 12 month Price to Earnings (P/E) ratio of 93.1 based on its trailing 12 month price to earnings (EPS) of $0.1 per share
Its forward P/E ratio is 17.9, based on its forward earnings per share (EPS) of $0.52
Over the last four years, Grifols has averaged free cash flows of $395,430,333.30, which on average grew 157.6%
GRFS's gross profit margins have averaged 42.6 % over the last four years and during this time they had a growth rate of -6.9 % and a coefficient of variability of 7.2 %.
Grifols has moved -25.1% over the last year compared to -14.8% for the S&P 500 -- a difference of -10.3%
GRFS has an average analyst rating of hold and is -16.5% away from its mean target price of $11.15 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.